More articles from Endocrine/Neuroendocrine Cancers

You have access
Role of PET / CT with 68Ga-DOTA-TATE in the evaluation of patients with medullary thyroid carcinoma
Enzo Silvera, Agustina Banchero, Renee Ortega, Eduardo Savio, Omar Alonso, Pablo Duarte and Juan Gambini

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3008;
You have access
Evaluation of treatment-naive high-grade neuroendocrine tumors with 68Ga-DOTA-RGD2 PET/CT and a comparison with 68Ga-DOTANOC PET/CT: a pilot study
Karthikeyan Subramanian, Rajender Kumar, Harish Goyal, Sanchay Jain and Venkata Krishnaraju

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3012;
You have access
Rising Frequency of Differentiated Thyroid Cancer in Younger Population.
Aniqa Jabeen

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3000;
You have access
Detection of suspicious lesions on F-DOPA PET in case of suspected recurrence of medullary thyroid cancer: comparison of intrapatient performance between early and late acquisitions
Mariagiulia Longo, Laurentiu Agrigoroaie, Théophraste Henry, Mohamed aymen Bettaieb, Dolly YAZGI, Corinne Balleyguier and Camilo Garcia

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3017;
You have access
Phase 1 study of no-carrier added 177Lu-DOTATATE (SNU-KB-01) in patients with somatostatin receptor-positive neuroendocrine tumors: The first clinical trial of peptide receptor radionuclide therapy in Korea
Hyun Gee Ryoo, Minseok Suh, Keon Wook Kang, Dae-Won Lee, Sae-Won Han and Gi Jeong Cheon

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3007;
You have access
Long-Term Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors of Unknown Primary (CUP-NETs)
Jingjing Zhang, Mengqi Shi, Harshad Kulkarni, Pek-Lan Khong, Xiaoyuan Chen and Richard P. Baum

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2996;
You have access
Prognosis and correlation of lactate dehydrogenase A and Warburg effect in differentiated thyroid cancer
Tian Tian, Hongyuan Dai and Rui Huang

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3002;
You have access
Special value of (99m)Tc-denatured RBC SPECT/CT combined with (68)Ga-DOTATATE and (18)F-FDG PET/CT or PET/MR in differential diagnosis and postoperative re-staging for pancreatic body-tail tumors
Xin-Yun Zhang, Ye Peng, Chao Cheng, Shuang Qiu and Chang-Jing Zuo

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2992;
You have access
Clinical analysis of influencing factors on therapeutic effect of radioactive iodine therapy in thyroglobulin antibodies positive patients with papillary thyroid cancer
Linna Guo, Yuanli Zhang, Huimin Li, Sijin Li and Xiaoshan Guo

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 3006;
You have access
Predictive factors of post-operative thyroglobulin <0.2 ng/ml and pre-ablation stimulated thyroglobulin > 10 ng/ml in differentiated thyroid carcinoma
Hongxi Wang and Rong Tian

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2988;

Main menu

User menu

Search

More articles from Endocrine/Neuroendocrine Cancers

Pages